NEWS COMMENTARY

Zymergen raises $400 million Series C

Published:
December 13, 2018
Coverage:
Accelerating Materials Innovation More...
Activities:
Investment
11177 thumb square
by Gihan Hewage
Truly disruptive

Zymergen had previously focused on improving its clients' strains – claiming scales over 100,000 tpa for strains and producing on the order of $100 million worth of product per year. Not only will Zymergen use this funding to double the capacity of its platform, but it also intends to use the funding to commercialize its own products. This raise highlights the strong potential for synthetic biology as a future manufacturing tool and ally to the agriculture industry – Zymergen's plan to commercialize strains from scratch, as opposed to optimizing existing strains, will provide a strong test of the efficacy of its platform, especially given the struggles of companies commercializing bio-based products in 2018.

For the original news article, click here .


Further Reading

Biosyntia

Company Profile | June 12, 2018

Develops engineered strains and fermentation processes for the production of small molecules using a suite of synthetic biology and metabolic engineering technologies  To date, the company has raised about $10 million, including $4.7 million Series A funding in 2018 Currently focuses on food ... Not part of subscription

Isobionics

Company Profile | January 3, 2019

Uses a double‑carbon bacterial fermentation platform for the production of valencene, nootkatone, beta‑elemene, and beta‑bisabolene; claims cost, purity, and supply advantages over conventional plant‑ and yeast‑based methods Primarily uses glucose as its main feedstock, but is working to ... Not part of subscription

FrieslandCampina gets green light for its human milk oligosaccharide ingredient from regulatory authorities

News Commentary | May 8, 2018

FrieslandCampina has recently obtained EU approval as well as GRAS status from the FDA for its human milk oligosaccharide (HMO) ingredient, 2′‑fucosyllactose (2′‑FL), closely following the recent approval obtained by its competitors for the same. With a projected product launch by the end of this ... Not part of subscription